patient-specific dendritic cell vaccine for melanoma

A patient-specific dendritic cell vaccine for melanoma is an individualized immunotherapy created by isolating a patient's own (autologous) dendritic cells and loading them ex vivo with antigens derived from the patient's irradiated tumor cells or tumor-associated antigens. The resulting cellular product is administered back to the patient as a therapeutic cancer vaccine. The mechanism of action involves the induction or enhancement of anti-tumor immune responses by presenting a broad repertoire of unique, patient-specific neoantigens to T cells, thereby stimulating cytotoxic T lymphocyte activity against melanoma cells. This approach aims to overcome tumor immune evasion and improve long-term survival in patients with advanced or metastatic melanoma[1][2][3]. Clinical trials have demonstrated feasibility, safety (minimal toxicity), and encouraging survival outcomes compared to historical controls[1][3]. Manufacturing typically involves generating short-term autologous tumor cell lines from resected tumors, preparing monocyte-derived dendritic cells from peripheral blood mononuclear cells using cytokines such as IL-4 and GM-CSF, pulsing these DCs with irradiated autologous tumor antigens ex vivo, then administering them subcutaneously—often in combination with adjuvants like GM-CSF[1][3].

Other names

patient-specific DC vaccine for melanomaautologous dendritic cell vaccine for melanomaDC–ATA